The challenge of HIV sequence diversity in the envelope glycoprotein

  • Laurence Vergne
  • Martine Peeters
Part of the Milestones in Drug Therapy book series (MDT)


One of the major characteristics of the human immunodeficiency viruses (HIVs) is their extremely high genetic variability, which makes HIV one of the fastest evolving among many other human pathogens. Viral heterogeneity is one of the classical means by which HIV evades the host immune system, and also leads to the resistance to various antiretroviral regimens. Highly active antiretroviral therapy to treat HIV-infected patients is mainly based on a combination of protease and reverse transcriptase inhibitors. However, resistance to these drugs, the persistence of latent viral reservoirs and long-term toxicities require the continuous need to improve these classes of drugs and to develop new drugs with other targets. Therefore, a new generation of drugs has been recently developed to inhibit viral entry into the cell.


Human Immunodeficiency Virus Envelope Glycoprotein Fusion Inhibitor Entry Inhibitor Gp120 Envelope Glycoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preston BD (1997) Reverse transcriptase and HIV-1 variation. Science 275: 228–229PubMedCrossRefGoogle Scholar
  2. 2.
    Keulen W, Nijhuis M, Schuurman R, Berkhout B, Boucher C (1997) Reverse transcriptase fidelity and HIV-1 variation. Science 275: 229–231PubMedGoogle Scholar
  3. 3.
    Hu WS, Temin HM (1990) Retroviral recombination and reverse transcription. Science 250: 1227–1233PubMedCrossRefGoogle Scholar
  4. 4.
    Zhuang J, Jetzt AE, Sun G, Yu H, Klarmann G, Ron Y, Preston BD, Dougherty JP (2002) Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol 76: 11273–11282PubMedCrossRefGoogle Scholar
  5. 5.
    Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123–126PubMedCrossRefGoogle Scholar
  6. 6.
    Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483–489PubMedCrossRefGoogle Scholar
  7. 7.
    Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582–1586PubMedCrossRefGoogle Scholar
  8. 8.
    Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn B, Kalish ML, Kuiken C et al. (2000) HIV-1 nomenclature proposal. Science 288: 55–56PubMedCrossRefGoogle Scholar
  9. 9.
    Schim van der Loeff MF, Aaby P (1999) Towards a better understanding of the epidemiology of HIV-2. AIDS 13: S69–84PubMedGoogle Scholar
  10. 10.
    Peeters M, Toure-Kane C, Nkengasong JN (2003) Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17: 2547–2560PubMedCrossRefGoogle Scholar
  11. 11.
    Vergne L, Bourgeois A, Mpoudi-Ngolle E, Mougnutou R, Mbuagbaw J, Liegeois F, Laurent C, Butel C, Zekeng L, Delaporte E et al. (2003) Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage. Virology 310: 254–266PubMedGoogle Scholar
  12. 12.
    Leitner T, Korber B, Daniels M, Calef C, Foley B (2005) HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: T Leitner, B Foley, B Hahn, P Marx, F McCutchan, J Mellors, S Wolinsky, B Korber (eds) HIV sequence compendium 2005, Los Alamos National Laboratory, Los Alamos, 41–48Google Scholar
  13. 13.
    Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barre-Sinoussi F, Brun-Vezinet F (1998) Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 4: 1032–1037PubMedCrossRefGoogle Scholar
  14. 14.
    Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J; WHO-UNAIDS network for HIV isolation and characterization (2002) Estimated global distribution and incidence of HIV-1 genetic subtypes during year 2000. J Acquir Immune Defic Syndr 29: 184–190PubMedGoogle Scholar
  15. 15.
    Julg B, Goebel FD (2005) HIV genetic diversity: any implications for drug resistance? Infection 4: 299–301CrossRefGoogle Scholar
  16. 16.
    Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Loussert-Ajaka I, Simon F, Saragosti S, Brun-Vezinet F (1997) Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 71: 8893–8898PubMedGoogle Scholar
  17. 17.
    Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB et al. (2005) Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192: 30–36PubMedCrossRefGoogle Scholar
  18. 18.
    Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J et al. (2000) Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 38: 3919–3925PubMedGoogle Scholar
  19. 19.
    Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V et al. (2000) Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitornaive individuals worldwide. HIV Variant Working Group. AIDS 14: 1489–1495PubMedCrossRefGoogle Scholar
  20. 20.
    Kantor R, Katzenstein D (2003) Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5: 25–35PubMedGoogle Scholar
  21. 21.
    Adje-Toure C, Bile CE, Borget MY, Hertog K, Maurice C, Nolan ML, Nkengasong JN (2003) Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02_AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d’Ivoire. J Acquir Immune Defic Syndr 34: 111–113PubMedCrossRefGoogle Scholar
  22. 22.
    Vergne L, Stuyver L, Van Houtte M, Butel C, Delaporte E, Peeters M (2006) Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 36: 43–49PubMedCrossRefGoogle Scholar
  23. 23.
    Rambaut A, Posada D, Crandall KA, Holmes EC (2004) The causes and consequences of HIV evolution. Nat Rev Genet 5: 52–61PubMedCrossRefGoogle Scholar
  24. 24.
    Madani N, Perdigoto A, Srinivasan K, Cox JM, Chruma JJ, Lalonde J, Head M, Smith AB, Sodroski JG (2004) Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 78: 3742–3752PubMedCrossRefGoogle Scholar
  25. 25.
    Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng T, Matton, Molinier S et al. (1999) Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr 20: 115–121Google Scholar
  26. 26.
    Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, Nakiyingi J, Rutebemberwa A, Morgan D, Weber J et al. (2002) Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 185: 1244–1250PubMedCrossRefGoogle Scholar
  27. 27.
    Briz V, Poveda E, Soriano V (2006) HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619–627PubMedCrossRefGoogle Scholar
  28. 28.
    Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V (2004) Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74: 21–28PubMedCrossRefGoogle Scholar
  29. 29.
    Roman F, Gonzalez D, Lambert C, Deroo S, Fisher A, Baurith T, Stauub T, Boulme R, Arendt V, Schneider F et al. (2003) Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 33: 134–139PubMedCrossRefGoogle Scholar
  30. 30.
    Cooper DA, Lange J (2004) Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 4: 426–436PubMedCrossRefGoogle Scholar
  31. 31.
    Aghokeng AF, Ewane L, Awazi B, Nanfack A, Delaporte E, Zekeng L, Peeters M (2005) Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa. AIDS Res Hum Retroviruses 21: 430–433PubMedCrossRefGoogle Scholar
  32. 32.
    Cilliers T, Patience T, Pillay C, Papathanasopoullos M, Morris L (2004) Sensitivity of HIV-1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 20: 477–482PubMedCrossRefGoogle Scholar
  33. 33.
    Poveda E, Rodes B, Toro C, Soriano V (2004) Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 20: 347–348PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2007

Authors and Affiliations

  • Laurence Vergne
    • 1
  • Martine Peeters
    • 1
  1. 1.Institut de Recherche pour le DévelopementUMR145 “HIV and associated diseases”MontpellierFrance

Personalised recommendations